Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
MANNHEIM, Germany - Affimed N.V. (NASDAQ:AFMD), an immuno-oncology company trading at $0.13 per share, is set to be delisted from the Nasdaq Stock Market following a notice from the Nasdaq Listing Qualifications Department. The stock has fallen 97% over the past year, according to InvestingPro data. The suspension of trading will commence at the opening of business on May 20, 2025, with a Form 25 Notification of Delisting to be submitted to the U.S. Securities Exchange Commission.
The decision is a result of several factors, including public interest concerns after the company’s recent insolvency filing, questions about the residual equity interest of current shareholders, and doubts about Affimed’s ability to maintain compliance with Nasdaq’s listing requirements. InvestingPro data shows the company’s market capitalization has dropped to just $2.2 million, with an Altman Z-Score indicating significant financial distress. The company, which has chosen not to appeal the decision, had filed for insolvency on May 13, 2025, at the local court in Mannheim, Germany.
Affimed specializes in developing therapies that harness the body’s innate immune system to fight cancer. Its proprietary ROCK® platform has produced a range of innate cell engagers (ICE®) that are currently in various stages of clinical development. Despite the financial setback, the company has been recognized for its innovative approach to cancer treatment. Financial data from InvestingPro reveals the company generated $6.28 million in revenue over the last twelve months, though it remains unprofitable with significant cash burn.
This news comes as a significant blow to Affimed, which has been committed to advancing its pipeline of cancer therapies. The company’s management team, comprised of experienced leaders in biotechnology and pharmaceuticals, has not released further plans regarding the future of the company’s operations or its assets.
The delisting notice is based solely on the press release statement from Affimed N.V. and serves as a critical update for investors and stakeholders in the biotechnology sector.
In other recent news, Affimed N.V. has reported promising results from its AFM24 drug for treating non-small cell lung cancer. The study indicated that patients with higher exposure to AFM24 experienced better response rates and longer progression-free survival. This development comes amidst a challenging period for the company, as Leerink Partners recently downgraded Affimed’s stock rating to Market Perform and reduced the price target to $0.39. The downgrade was attributed to concerns over Affimed’s ability to secure funding and changes in the regulatory landscape affecting cell therapies. Additionally, Affimed has received a notification from Nasdaq regarding its stock price failing to meet the minimum bid requirement for continued listing. The company has until October 13, 2025, to regain compliance or potentially transfer its securities to The Nasdaq Capital Market for an additional compliance period. These recent developments reflect both the potential and challenges facing Affimed as it navigates the complex landscape of immuno-oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.